mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, has appointed Jurgen Van Broeck as Chief Executive Officer.   Broeck, who has served as Global Commercial Director since June 2023, brings experience and a proven track record in the pharmaceutical and biosimilar industries.   Prior to his new role, Broeck was at the forefront of mAbxience’s strategic initiatives, overseeing all commercial, business development and market access activities. He ha...